•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730426 | PMC |
| http://dx.doi.org/10.1016/j.gore.2023.101311 | DOI Listing |
Publication Analysis
Top Keywords
ovarian carcinosarcoma
8
response low
4
low her2-expressing
4
her2-expressing ovarian
4
carcinosarcoma trastuzumab
4
trastuzumab deruxtecan
4
deruxtecan case
4
case report
4
report •treatment
4
•treatment options
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!